Hematology vs Oncology — Deal Terms Comparison

Hematology Median Upfront

$604M

Total: $3.0B

Oncology Median Upfront

$258M

Total: $1.6B

Hematology Royalties

8.5%-16%

Tiered to 20%

Oncology Royalties

11.8%-19.3%

Tiered to 23.3%

Model Your Deal

Market Analysis

Hematology and Oncology represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 hematology deals carry a median total deal value of $3.0B with $604M upfront, compared to $1.6B total value and $258M upfront for oncology. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

Deal structures differ across therapeutic areas. Hematology deals allocate 20% to upfront and 80% to milestones, while Oncology deals split 16%/84%. Development milestones are $500M for hematology versus $345M for oncology, reflecting the different clinical trial designs and approval standards in each area.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do hematology and oncology deal terms compare?

Hematology Phase 2 deals average $3.0B total value ($604M upfront), while Oncology deals average $1.6B ($258M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.

Which therapeutic area commands higher royalty rates: Hematology or Oncology?

Hematology base royalties range from 8.5% to 16%, while Oncology royalties range from 11.8% to 19.3%. Royalty rates reflect pricing power, competitive dynamics, and patent protection characteristics specific to each therapeutic area.

What drives the deal value differences between hematology and oncology?

Key factors include addressable patient population size, clinical trial costs and timelines, regulatory pathway complexity, pricing and reimbursement dynamics, and competitive landscape density. Hematology and Oncology each have unique value drivers that shape deal economics.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need a decision for one asset?

The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.

Configure Brief — $2,500About 30 data-backed pages · Invoiced at intake · 30-minute walkthrough